Wagner Paul A. 4

4 · Forte Biosciences, Inc. · Filed Apr 3, 2026

AI-generated summary of this filing

Updated Apr 3, 2026

Forte Biosciences (FBRX) CEO Paul Wagner Receives 2,402 Shares

What Happened

Paul A. Wagner — listed as Director and noted as CEO, Secretary and Chair of Forte Biosciences (FBRX) — had restricted stock units (RSUs) convert into common shares on April 1, 2026. The filing shows two conversions of 1,250 RSUs each (total 2,500 shares). To satisfy tax withholding, 98 shares were surrendered at $24.86 each, totaling $2,436. Net new shares received by Wagner = 2,402 (2,500 − 98). The RSU conversions carried no exercise price.

Key Details

Transaction date: 2026-04-01; Form 4 filed: 2026-04-03 (filed timely).
Conversion entries: two "M" codes (exercise/conversion of derivative) for 1,250 shares each (aggregate 2,500).
Tax withholding: "F" code — 98 shares surrendered at $24.86/share for $2,436.
Shares owned after transaction: Not disclosed in the Form 4.
Footnotes: Each RSU represents a contingent right to one common share. Vesting is subject to continued service and occurs quarterly per the issuer’s 2021 Equity Incentive Plan (1/16th on each Quarterly Vesting Date as defined).

Context

This was RSU vesting/conversion (an award becoming stock), not an open-market purchase or a deliberate sale. The only disposition was the routine share withholding to cover taxes.
For retail investors: awards/vests increase insider ownership but do not directly signal buying conviction like open-market purchases. This filing appears routine and was reported within the normal Form 4 window.

Form 4

Period: 2026-04-01

DirectorSEE REMARKS

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-04-01+1,250→ 84,428 total
Tax Payment
Common Stock
2026-04-01$24.86/sh−98$2,436→ 84,330 total
Exercise/Conversion
Restricted Stock Units
[F1][F2]
2026-04-01−1,250→ 3,750 total
→ Common Stock (1,250 underlying)

Footnotes (2)

[F1]Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
[F2]Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to the award shall vest on each Quarterly Vesting Date (as defined below) on or immediately following February 1, 2023. For purposes of this RSU Award, "Quarterly Vesting Date" with respect to any calendar year means January 1, April 1, July 1, and October 1.

Signature

/s/ Paul A. Wagner, Ph.D.|2026-04-03

1 file